Loading...
XOSL
TRMED
Market cap25mUSD
May 02, Last price  
2.32NOK
1D
1.75%
1Q
-10.08%
Jan 2017
-97.60%
IPO
-92.27%
Name

Nordic Nanovector ASA

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-11.99%
Revenues
0k
Net income
-42m
L+58.91%
-417,075,000-441,303,000-311,241,000-26,561,000-42,208,000
CFO
-24m
L-63.02%
0-398,206,000-403,458,000-409,079,000-64,090,000-23,700,000

Profile

Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. The company was founded in 2017 and is headquartered in Oslo, Norway.
URL
https://www.nordicnanovector.com/
IPO date
Jul 07, 2014
Employees
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
3,309
4,080
28,773
Unusual Expense (Income)
NOPBT
(3,309)
(4,080)
(28,773)
NOPBT Margin
Operating Taxes
430
1,000
311,241
Tax Rate
NOPAT
(3,739)
(4,081)
(340,014)
Net income
(42,208)
58.91%
(26,561)
-91.47%
(311,241)
-29.47%
Dividends
Dividend yield
Proceeds from repurchase of equity
114,300
147
250,808
BB yield
-18.43%
-0.07%
-186.19%
Debt
Debt current
400
159
Long-term debt
1,000
159
Deferred revenue
Other long-term liabilities
100
Net debt
(122,000)
(41,767)
(96,234)
Cash flow
Cash from operating activities
(23,700)
(64,090)
(409,079)
CAPEX
(100)
(5,628)
Cash from investing activities
1,300
6,276
(2,464)
Cash from financing activities
104,000
(332)
228,125
FCF
(4,131)
(4,551)
(334,609)
Balance
Cash
123,400
41,767
96,552
Long term investments
Excess cash
123,400
41,767
96,552
Stockholders' equity
(7,000)
25,856
(2,708)
Invested Capital
344,900
246,069
67,470
ROIC
ROCE
EV
Common stock shares outstanding
235,793
174,787
115,130
Price
2.63
103.88%
1.29
10.26%
1.17
-94.85%
Market cap
620,136
175.03%
225,475
67.39%
134,702
-93.75%
EV
498,136
183,708
38,468
EBITDA
(909)
(3,363)
(17,571)
EV/EBITDA
Interest
Interest/NOPBT